水果视频app免次数版下载,极速小说网,蓝导航accessibility 18禁日本,青蛙视频app,天天看片ios下载安装accredited 草莓成视频人app下载污,91福利社区 永久体验区,蘑菇视频手机版下载active 水果视频app入口,国产大香蕉,午夜草莓成视频人app下载activity 奶茶视频高清免费,美国adc,久草福利最稳定的资源站aim 蜜桃直播app下载官网,51影豆网,彩色直播官网alarm no视频,水果视频下载app,荔枝视频下载app最新版align-bottom 猫小姐直播app,91短视频,茄子在线视频appalign-center-horizontal 食色原创视频,夜未央动漫,第一免费成人appalign-center-vertical 香草视频软件下载,bt福利,小优app在线视频align-left 抖阴app下载,雪梨视频app官网下载,花椒直播官网align-right 春意影院网站入口,七次郎青青草,最火的彩色直播align-top 猫咪社区app在线看片,午夜理论,s8精品视频在线观看anchor 青青草大香蕉,bbav免费视频,s8spangel 香草成视频人,18禁止观看强奷视频,日本影城annoyed 大人资源,扶老二,水蜜桃appapple 欧美爱爱直播,蘑菇盒子软件下载,菠萝蜜视频在线视频archive 极品,菠萝蜜视频下载,狼友聚导航arrow-down 艳春楼视频,乐思啪导航,兔牙视频下载arrow-left 终点分享,小妖精直播app手机版下载,爱x视频arrow-right 香蕉视频app下载安卓下载,成人快手抖音短视频,最新版黄瓜apparrow-up 草榴视频ap,avmemo,红杏视频apparticle 小辣椒直播app下载,在线观看菠萝蜜视频污,午夜影院官网at-sign 花间直播无限礼物版,樱桃视频―首页,向日葵app官方最新版award 月亮视频看片app下载,卡哇伊ios直播官网官方网站,2019夜未央app官方下载balance 成版人性视频app菠萝,bt包菜,91青青草视频在线观看balloon 青青草视频下载,久草色香蕉视频在线,豆奶福利短视频bandaid 骑女友现场直播,菠萝视频就要爱做出来,水果视频app下载污barcode 快猫成年版抖音,老司机推荐福利视频app ios,魅吧tvbell aio search,91手机下载软件,c.c动漫bicycle 花间女生直播,免费可以看污app食色,娜鲁湾论坛binoculars 老司机抖音,九鬼导航,久久福利导航blind 水果视频扫码下载安装,av bobo下载,香蕉视频app免费下载boat 菠萝蜜视频app在线爱,8茄子直播下载,卡卡影院book-closed 久久久e热视频,蝌蚪窝下载,花间应用下载book 小妖精app直播安卓下载,水多直播平台视频,小棉袄直播破解盒子bookmark adc影院0adc影库,豆奶app ios下载地址,法克视频bookmarked 小姐姐直播最新版本,花间娱乐下载,食色原创视频books 王妃直播app,水果视频ios官方下载,小辣椒视频污版免费bottle 抖抖直播官网,心上人新版直播,免费下载 菠萝视频appbriefcase 人人磁力,茄子视频污官网下载,表妹破解版brush s8视频网站在线观看,小棉袄直播ios,色老板凹凸视频bug 91app苹果最新版,蜜桃直播app官网下载,黄版本抖音安卓bullhorn 丝瓜视频看污片,kitty官网,小辣椒j3视频在线观看bus 饭团扑,月亮视频app破解版,成版人直播app花椒cabinet 菠萝社区官网,小姐姐官网app二维码,骑女友网址cake 骑女友网在线,3atv精品视频,你懂的福利视频合集calendar v聊苹果下载,依依影院在线,fulao2网址是多少camera 天天看片大陆版破解版下载v1,春意在线观看,豆豆视频app官网下载car 猫咪社区app在线域止,青春草原精品资源视频,在线下载樱桃cash 漫社堂,小奶狗app怎么下载,孤狸视频下载免费certificate 最新青青草安卓版下载,表妹直播邀app邀请码,茄子人成年短视频chalk kitty视频app,比思论坛,trannyonechart-bars 卡哇伊下载地址二维码,九尾狐短视频无限观看,透湿网chart-line 小奶狗appios版,蝶恋花,秋葵视频app二维码chart-pie 夜未央二维码,抖阴短视频app二维码,秋葵视频在线观看免费chat 食色下载社区,小可爱直播,樱花视频checkmark 番茄app最新下载地址,秋葵视频官网,苦瓜视频在线下载appchevron-down 小奶狗app黄,五月天官网,s8视频下载安装chevron-left 豆奶视频app苹果安卓版,小姐姐短视频app下载,下载香蕉视频破解版chevron-right 尤物视频,食色成人原创自拍社区,黄瓜app官网你懂的chevron-up 蘑菇网络下载安装,研究院网站app,http荔枝视频circle-arrow-down 红番茄视频成年在线,秋葵视频手机在线看,d2下载circle-arrow-left 小优视频app在线播放,v聊直播合法吗,吾本色circle-arrow-right 海外adc网站,ox最新福利,小花椒app下载ioscircle-arrow-up 嘿嘿连载,菠萝蜜视频免费下载,花椒直播 mp4circle-backward 小优影院app,水果视频app扫码下载,菠萝蜜视频app苹果circle-checkmark 青青草视频成人,在线观看午夜影院app,蝌蚪下载circle-chevron-down 九尾短视频app官网,成人抖音app大全,爱爱大全circle-chevron-left 浪浪视频色版app,v聊app下载安装,微杏破解版circle-chevron-right 月亮视频在线下载,小奶狗最新地址,青青草在在观免费福利线观看circle-chevron-up 怡红院成人,菠萝蜜app下载苹果版,宅男appcircle-cross 猫咪破解版下载,色老板视频线观看在线,妖图circle-eject 心上人直播id62,午夜影院体验区60秒,花椒视频app下载地址circle-exclamation 花间直播的秘密入口,猫咪视频在线浏览,抖阴短视频app官网下载平台circle-facebook 诺诺导航,狐狸色迅雷下载,v聊天circle-first 小妖精app下载地址ios,食色app最新版下载,黄瓜视频ios深夜appcircle-forward 天天看片,熊猫直播ios下载,kitty搜索circle-googleplus 成人快手破解版,panda下载安装,avflimcircle-gust 手机私人高清影院,蜜桃视频下载,老司机app免费下载circle-last 香蕉网在线观视频,柠檬直播下载,荔枝视频app在线观看污片circle-linkedin 心上人直播免费版,菠萝蜜视频无限制观看污,小猫猫导航circle-minus 老司机抖音,九鬼导航,久久福利导航circle-next 熊猫直播官网下载,花友app下载,下片片circle-pause 四虎最新网址,禁18怕啦啦啦视频网站,小棉袄官网circle-play-thin 茄子视频破解无限,小妖精视频app下载安装,gelboorucircle-play 番茄社区福利app无限看,adc手机在线视频,牛郎导航circle-plus 茄子直播app无限制破解版,表妹直播官网下载,情趣小镇circle-previous 免费直播秀,中文视频,菠萝蜜影视在线观看circle-question 91直播ios版下载安装,丝瓜成人app,骑女友登录网址circle-stop 夜色视频站,久久热人视频,狐狸视频最污的一个视频circle-twitter adc影院手机在线,小辣椒视频安卓,f2富二代app官网circle 蘑菇视频官网app无所不在性,蜜桃视频app官网,老撕鸡app下载污污污clipboard-check 夜色成年视频,七次夜郎在线网站,黄瓜直播间clipboard 月亮视频播放器下载,小棉袄软件直播,水果视频下载app苹果版clock 91短视频抖音版下载,兔牙视频app下载,小辣椒视频苹果app下载cloud-database 荔枝软件下载,禁18怕啦啦啦网站,草莓图库cloud-download 王妃直播平台,卡哇伊裸直播app,91免费免费观看在线cloud-fog s8视频在线观看下载,小妖精官网无下载安装,220直播平台cloud-gear fulao2下载最新版,自由点导航,蜜蜂在线官网cloud-lightning 水中色大型综合av,狐狸视频超污版,91福利社区加入cloud-lock 精品呦女资源,小妖精去哪下载,青青伊人cloud-rain 杨幂横店门,3d游戏,丝瓜直播下载链接cloud-snow adc影院0adc影库,豆奶app ios下载地址,法克视频cloud-sync 小狐仙直播app官网下载,深度撞击,青青草视频免费观看cloud-upload 黄瓜视频污下载app,她也色视频,懂片帝视频appcloud 窝窝网站,pear社区国外版,月亮影视appcocktail-glass 有基zz视频,国产夜猫视频在线观看,kitty磁力兔子code 猪泡泡影院,s8看视频,精灵福利导航combine hot导航,菠萝蜜视频app偷拍视频,番茄社区性直播comment-fill 小棉袄海外直播app,蘑菇视频app网站,小姐姐二维码官方软件comment 四虎免费紧急入口,豆奶app苹果版,快狐成人短视频appcomments 后宫视频,草菇视频app下载,亚洲伊人久久综合图片compass 香蕉玉米视频app,2048核基地,食色视频app下载地址最新confused 魔王家,喏喏导航,青娱乐极品视频视觉connect s8sp视频网站在线观看,夜色直播appios软件,水蜜桃视频app最新破解版下载construction-cone 魅影夜色app,夜色直播宝盒破解版下载,大香蕉狼人construction 番茄视频app无限播放,小辣椒直播app软件平台,全球直播contacts 怡红院免费全线观看,九尾短视频在线观看,香蕉97超频视频在线cool 花间直播网站直接进入,茄子更加懂你app污,午夜影院费试看黄copy 食色app下载短视频,四虎影在永久在线观看,花间污直播在线观看credit-card 卡哇伊直播平台app,pear雪梨二维码,可爱萝莉crop 小姐姐直播,久草在线福利视频在线播放,香蕉视频app官网cross 花间直播 肉 免费,夜色直播下载,乐百在线crown moto电影,热爱小姐姐,小奶狗视频安卓版cube 大香蕉免费下载,猫咪成年短视频下载,18禁成年动漫网站视频database 小辣椒软件下载,奶茶官网强东看了都说好,18厘米delete 蘑菇短视频,无码高清视频,污香蕉视频app网址design 萝卜视频app下载污,月半楼,萝卜app软件下载desktop 月亮播放器app官方版下载,免费荔枝视频app男人影院,fulao2最新版diamond 小奶狗直播飞机,粉嫩女孩,四虎影库在线永久影院免费观看dice 夜色宝盒破解版app,骑女友18网,成版人豆奶app网站dinner 食色软件app成人抖音,夜色直播间,免费破解版高清无限看disconnect 菠萝蜜视频在线播放观看,芭提雅导航,小棉袄大秀平台document 色中色视频网站,成版小奶狗直播app破解版,春意影院免费版视频download s8视频免费视频,熊猫tv,东方四虎私库在线观看drawer 8x8x,十八禁漫画大全无遮挡,91富二代视频网站dream 污污玉米视频软件,情趣魅惑,秋葵app苹果版下载droplet 夜色直播app破解版 ios,夜色世界app,小辣椒直播app在哪里下载dumbbell 日本爽爽影院18禁,丝袜文学,食色life官网earth 熊猫社区官方下载,苦瓜视频app苹果,亚洲怡红院edit xy16app黄瓜ios,肉蒲团导航,成版人短视频appegg adc官方网,9uuapp官网,台湾s8视频app下载ellipsis 亚色中文网,美女vip图,成人帝国enter-down 东京热在线资源,汤姆叔叔网站入口,豆奶安卓enter-left 熊猫tv下载,91国产偷拍,歪歪资源网enter-right momshere,av蜜桃,玖草堂enter-up 食色精选app,app老司机你懂的,番茄色appenter 猫咪社区网页版在线入口一,月亮视频网站,有声有色envelope 花椒最新版本下载,91国产app破解版ios,怡红院电影evil 久久热免费啪啪视频,水果视频app官网ios,爱情海直播iosexclude 大熊猫在线视频,ftopx,夜色撩人直播appexit-down 番茄视频app直播无限制,青青草视频网站,擎天柱exit-left 草莓app在线看,142adc,18禁视频exit-right 小姐姐app下载,蘑菇视频app黄,董小姐在线exit-up selaoban色老板.com,香蕉视频老版app下载,食色成人抖音破解版exit 水果视频app免次数版下载,极速小说网,蓝导航expand pandatv下载,月亮视频软件下载,夜色直播苹果二维码下载eye-dropper 表妹直播官网苹果下载,小妖精直播ios破解版下载,被窝电影eye 懂片帝苹果破解版下载,花和尚,adc影库119影库facebook 樱桃精品,花心直播官网,91现在的网站变成多少了factory 最新版本花椒下载,天使福利ap,小辣椒视频苹果版app下载feather 花椒直播助手app下载,91福利社区试看一分钟,色狐狸file-audio 含羞草app免费版,木瓜福利影视大全,91自拍视频网file-code 晴色av,fulao2下载ios,环亚无码超清file-image 嘿嘿连载官网下载,心上人软件邀请码,小狐狸直播app网站file-video 成人抖音ios直接安装,ios香蕉视频app,小优视频最新版下载file-zip 小伊伊,扶老二fulao2安卓版,无毒无广告在线看avfile 花间女生直播,免费可以看污app食色,娜鲁湾论坛film-play no视频,水果视频下载app,荔枝视频下载app最新版find 番茄视频app无限播放,小辣椒直播app软件平台,全球直播fire 蘑菇影视在线播放,老司机小说,雪梨视频appfirst-aid s8视频app在线下载,adc视频网站,免费下载s8视频flag 含羞草app免费版,木瓜福利影视大全,91自拍视频网flip-horizontal 恋夜秀场安卓,越色之界,久草大香焦伊在线flip-vertical 网红主播秀,废柴视频网,久草久久热floppy-disk 水果视频官网在线观看,提姆正妹,av女优榜folder adc影院0adc亚洲,性福宝视频app下载,花椒私人视频appfootprint 水果视频ios在线看,最新色中色,蘑菇app下载frame 老司机福利在视频在ae8,91app网站哪里有下载,茄子成视频人app下载funnel 黄瓜直播网址,魅色论坛,抖阴app安卓下载gamepad 嘿嘿连载app污,夜未央ios下载,色中色最新地址发布器gas 熊猫社区1·11,雪梨枪20分钟视频,萝卜视频最新版苹果版下载gear ftop壁纸,怡红院全免费播放视频,tktubegift 色中色视频网站,成版小奶狗直播app破解版,春意影院免费版视频glass 黄瓜app在线观看视频破解版,草莓视频app下载地址,久久热小说glasses 小优ios下载,bitch导航,农夫avgoogleplus 猫咪app官网破解版,月亮app最新版,91tv二维码下载appgraduation 番茄视频app无限制观看,91app官网下载安装,变态食色appgrin-evil 猪猪短视频app,夜色直播app平台下载,九尾狐短视频grin 精选视频库,秋葵视频无限次数版,心上人视频group 鲁先生app 安卓版,心上人官网app,极品bbgun 新版猫咪官网,香蕉视频新版下载ios,月亮app永久免费下载gust 漫域,bt之家,66热hamburger bt-btt,浪潮免费app,外国在线18禁视频网站hammer 看微拍,午夜福利50集在线看下载,成人快手视频happy-grin 動漫狂,18porn,sankakuhappy 台湾mm私密直播,水果视频app看片 视频,南瓜视频最新版下载headset 花间裸身直播app 下载,木瓜影视在线观看视频,哈密瓜app无限播放heart-fill 食色直播,澄海花心直播平台下载,夜趣福利所第一导航福利500heart 大姐姐导航,免费看各种人妻主播,超级先生history 食色福利软件,69热性视频,小可爱直播home 小仙女直播软件,愉悦小说,青青草成年视频手机版icons 七秒鱼app官网下载,水果视频app下载,菠萝蜜官方inbox 春意小视频,雪梨视频,花心app苹果intersect 猫咪社区官方在线入口免费,蘑菇视频免费下载,avappipad adc影院adc037,菠萝蜜国际影片加速线路1,芒种视频iphone 手机在线,91社区视频app下载,小辣椒live直播二维码key 月漫app官网下载,左爱视频,花心app破解版keyboard d2天堂在线,落叶知秋,7160荔枝视频看片keyhole 色妹子,伊人网女优,茄子成人app官网下载安装knife 91网址怎么搜不到了,猫咪短视频app下载地址,熊猫社区可下载网站lab 花友在线直播,熊猫tv官网下载,猫咪社区app在线官方网址lamp 老司机的软件库,菠萝蜜视频下载安卓版,富二代官网laptop air免費av,中外导航,老司机免费精福利视频leaf 爱爱你app,avme磁力链,青青草大香焦在线综合视频leave-down 深夜草莓视频app污,蝌蚪窝视频在线播放,咪咪视频在线观看leave-left 黄瓜视频ios下载,小棉袄app下载直播,久久热手机视频leave-right 花心直播,唐门导航,vvmmdleave-up 含羞草老版本,s8sp影视,007系列library 色色啦,91短视频网络异常,青青草网站lifebuoy 8x影库,宅男视频,色老板在线观看高清lighter 花友app一对一,芒果app下载视频,91视频网站观看免费lightning-bolt av基地网,av制服师生,伊人成色综合网link 懂片帝app 最新版,二狗子视频,av秘籍linkedin 黄瓜视频官网下载,咪咪视频苹果app下载,花椒直播视频下载list 香草视频软件下载,bt福利,小优app在线视频location 翼夢舞城,3d hentai,骚气满分导航lock 青狐视频app各种大片,ue资源站,fulao2安卓国内载点3lotus 超91国产高清视频下载,s8sp视频在线观看免费,小辣椒直播下载mad 快猫ios成年破解版,caoli社区最新2019入口,九大官人论坛magic 小姐姐直播app官方网站,青青草在现线久观看2020,花椒视频app1magnet 蜜桃社区app官网,雪梨pear看片,久草官网mallet 18禁色大尺度视频免费播放器,食色精选原创在线播放,萝卜视频app二维码man 手冲坊,小黄人部落,菠萝app爱就要做出来网址map 红果福利tv,菠萝蜜国际视频,东京热男人av天堂medal 超91国产自拍视频情侣,fulao2软件官网下载,蜜蜂社区 欧美 视频播放meet-down 色中色软件,精选女优集,942pornmeet-left 小奶狗污下载,久久热精品只在这里,小辣椒视频app下载污污污meet-right 樱桃视频app在线网站,夜色吧资源,菠萝蜜污app下载meet-up 蜜桃社区app官网下载,老版花间直播,色狐狸最新视频mic-mute 黄瓜视频最新二维码,富二代在线观看视频网址,合欢影院app18岁mic se69高清,西瓜影院,91在线视频app官网下载minus sg99xyz下载丝瓜视频,食色在线网站,豆奶app下载moon 食色官方app下载,水中色视频,免费裸聊直播mouse 小辣椒直播间,深夜福利免费直播app,茄子视频免费move avtt天堂网2014东京热,黄瓜app苹果版下载,熊猫avapp安卓下载music-note 网红护士,青青草久碰,雪梨app官方网站music 水多app下载安装,蝌蚪官方app下载安装,熊猫聊天app下载mustache 天堂导航,18禁电影网站,花椒直播app 下载mute sm心灵社区,七次郎是针对绿色华人站之一,花间直播安卓版下载安装navigation 禁18怕啦啦啦视频,街拍第一站,水果视频neutral 69免费资源,咪咪邀请码多少,久草久热appnews 狐狸视频下下载,食色ios最新下载,小棉袄下载options 玉米视视频手机版下载安装,草莓视频888app下载,fulao2官方网iosoutlet 小棉袄直播app苹果版,樱桃福利导航,大师导航paint-roller 色色吧视频,iqq線上看,小棉袄在哪个平台下载paintbrush 青青草app下载,奇米影视第四色首页,豌豆apppair fulao2app苹果版下载,91成年app,爱看风云paper-plane 百思特视频,狐狸视频app免费下载,最新片大站paperclip 新色中色,花椒直播录像视频大全,小棉袄直播app软件下载papers 大香蕉久草热,夜色live直播破解app,幻想次元paste 网络最新艳照门视频,水果视频污app下载,菠萝蜜视频app安卓patch s8视频app在线下载,adc视频网站,免费下载s8视频paw 水果视频app无限观看,绝色干,花椒视频网pen 春来视频,av天堂东京热国产,小性感直播app官网下载pencil 茄子视频网站,狐狸视频色板app下载,伊丽讨论坛phone 91 chnese国产app,小优视频下载,新抖抖app官网下载photo 水果视频下载,青青草首页,舒心园picture 猫咪直播app官网,bt搜索,91b在线pin 丰乳肥臀,午夜影院app在线1,番茄在线资源在线观看视频pine-tree 春意官网,91抖音版,菠萝蜜视频免费视频plane 网红福利直播,骚虎视频安卓app无限观看,avniceplay 66影视网,小奶狗官网最新地址,thefappeningplaylist 熊猫影院软件下载,春意影院app,春暖花开plug-cord 最新菠萝蜜视频,不收费的成人app,花间大尺度直播appplus 王妃直播app,水果视频ios官方下载,小辣椒视频污版免费podium 大香蕉网在线,色图吧,91黄色power 快狐视频在线观看,小辣椒直播app,台湾uu聊天室presentation 午夜影院7cdy旧版,bt目录,七次郎在线观看printer 卖肉直播破解版免费,富二代在线视频在线观看,小姐姐183直播平台下载profile 想要app网站,菠萝蜜app视频黄,七秒鱼官网app下载pulse 青椒视频app下载,放放水av,苦瓜视频下载地址puzzle 大长精,嘿嘿连载小说,天天看片手机版下载app安装question 水果视频免费下载安装,cartoontube,桃子视频quote-close 花椒直播旧版本下载,四虎影视下载,ios香蕉视频app官方下载quote-open 水中色大型综合av,狐狸视频超污版,91福利社区加入radio 老司机在线视频免费看,v聊都能干啥,小棉袄视频下载安装rank1 性直播app,食色官网,91最新视频app下载rank2 卖肉直播小可爱,小可爱直播在线,18禁真人床震无遮挡rank3 美色全球,碎特小电影,怡红院网站reception 91在线夫妻,色中色 最新ip,久久热影音资源网recycle avgle,小姐姐182app安卓下载,水果视频app在线观看视频redo 小优视频app在线播放,v聊直播合法吗,吾本色refresh 水果视频官方官网,宅宅愛動漫,萝卜视频看片破解版register 小辣椒成版人性视频app,美茓视频,成人黄瓜视频reply-all 水果视频扫码下载安装,av bobo下载,香蕉视频app免费下载reply adc免费手机版,狐狸视频app大片,scatpornroad-sign 茄子的黄软件,91视频直播网,猫咪短视频下载网址rocket 黄瓜视频深夜神器app下载,超91国产自拍视频,2019门事件ruler 水果视频ios在线看,最新色中色,蘑菇app下载sad 午夜诱惑app,汤姆叔叔网站,天上人间scissors d2天堂破解app下载,七次郎是针对全球华人绿色,表妹直播官网破解版screen 猪猪短视频app,夜色直播app平台下载,九尾狐短视频search 美女在线福利app,苦瓜视频污app,美空网share 永久免费ap,心上人直播平台破解版,1168avshield 啪啪鼓掌av,懂片帝最新版ios,且听风铃ship 嘿嘿连载下载地址最新版,小辣椒视频,七秒鱼shirt 吉哩哩,人妻少妇偷情,环亚无码超清资源shocked 四虎免费紧急入口,豆奶app苹果版,快狐成人短视频appshrink 夜猫男男同志视频片子,东京热1迅雷下载,夜色小说网shuffle 鱿鱼tv,91高清国语对白,扶老二官方网站signal 铁牛app网站,爱爱你直播官方下载,水果视频官网在线下载sitemap 飞机导航,v聊破解,熊猫tv吧skull s8最新版本,气球视频官网,夜未央直播app官网smartphone 小棉袄大秀app,狐狸视频app,狐狸视频app下载污网站smile 熊猫tv下载,91国产偷拍,歪歪资源网speed-fast 小辣椒一级视频,怡红院直播app,蜜情园首页speed-medium 雪梨pear下载地址,夜趣第一福利官方导航专业,妖精直播破解版下载speed-slow 草莓视频在线观看免费,食色视频app官方网站,粉色影院spell-check 搜视频网,菠萝蜜视频app色,食色短视频下载网址square fulao2下载,91手机版app,萝卜官网首页subtract 东京热影视在线观看,玖玖av,黄瓜app怎么增加次数sun s8s视频在线观看,菠萝蜜在线视频观看,各大资源在线秒观看sync 水果视频app苹果下载安装,久草资源站免费2016,kitty直播 app官网syringe fulao2宅男神器,熊猫视频app下载,顶天立地导航tab 萝卜视频app在线观看视频,菠萝蜜app下载平台,月亮视频下载tablet ios成版人app破解版,午夜萝莉大秀直播,懂片帝破解版下载tag 扶老二神器下载,茄子视频在线观看,小姐姐直播观众版怎么下载tags 魅力av,扶老二app下载,简单av网target 花椒直播破解版ios,cm88.tw草莓视频下载app,香蕉视频无限次观看teacup 快手抖音福利短视频,富二代wwwf2d,长春宫terminal 老司机午夜神器app,卡哇伊 呦幼,丝瓜视频破解版下载看片thumbs-down fulao2下载最新版,自由点导航,蜜蜂在线官网thumbs-up 花间app如何下载,杏趣直播软件,sm在线ticket 18禁日本,青蛙视频app,天天看片ios下载安装tiles 桔色视频,谷歌资源,香蕉影院app官网下载timer 小辣椒视频app二维码,九尾狐app高清,食色视频appios下载toilet-paper 水果视频app下载ios版,d2天堂视频app污,音色短视频无限次数版tongue 银漫社,adc国际影院在线,菠萝蜜视频最新地址发布页tools 爱看,91短视频,想要导航网页trailer 香蕉视频app网站入口,在线观看短视频网站,香蕉视频app官网下载train 小可爱官方app,猫咪手机短视频,大主宰transmission jav研究所官网,91自拍视频在线观看,凸凹视频trash 软妹子社区,蝌蚪窝最新视频,男女生视频tree 小仙女成年直播软件,花椒小视频怎么下载,秦先生91视频迅雷下载trophy 嘿嘿连载小说app,渣男研究所,冬瓜皮truck 小棉袄直播官方下载链接,浪浪视频色版,小黄鸭导航tv 木瓜视频大全在线观看,番茄社区黄版直播,老湿三分钟免费twitter 花间ios下载安装,小仙女直播app黄,辣椒视频在线appumbrella 小辣椒视频ios,月亮视频ios在线安装,v聊undo 小棉袄直播app下载,磁力链接,草莓app色版unlink 水果视频成年版app下载,丝瓜直播app官网,淫水导航unlock 漫社堂,小奶狗app怎么下载,孤狸视频下载免费upload 花间直播,食色抖音app安卓,咪咪app的邀请码user 午夜影院7cdy,久久热久久网久久影院,骑女友影音先锋视频users 小可爱直播ios下载链接,快狐app,adc网站亚洲volume-high 花椒福利在线视频,青娱乐极品视觉盛宴,温婉导航volume-low 手机版小可爱直播,小辣椒成版人性视频在线,怡红院免费的全部视频volume-medium 水果视频苹果下载,台湾s8spcom视频,熊猫tv下载安装volume 食色直播苹果版下载,国产富二代短视频在线观看,四虎首页影库warning 街拍vip网,蜜桃直播软件app,富二代app官网下载ios直播wheelchair 抖抖app同性,涩播,性吧导航wifi 久草网偷偷要,琪琪视频,茄子视频无限次数版wink 妙少妇视频,花心app官网,彩色直播appwoman 楼凤小姐信息,pear官网二维码,七色图库wondering 蜜芽视频,菠萝蜜视频在线观看视频,猫咪视频播放器wrench 雪梨app邀请码图片,fulao2ios下载,91在线国产av自拍zoom-in 茄子视频福利app直播,久草网在线,春意影视网站zoom-out

Website:

Share:

Invest in Monogram Orthopaedics

Linking 3D printing, machine learning, and robotics for high precision implants

  • $5,082,184Amount raised
  • 2,286Total investors
  • $4.00Share Price

Purchased securities are not currently tradeable.最终痴汉电车3 Expect to hold your investment until the company lists on a national exchange or is acquired.

Monogram Orthopaedics is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained both here and below.最终痴汉电车3 The contents of the Highlights, Term Sheet sections have been prepared by SI Securities, LLC and shall be deemed broker-dealer communications subject to FINRA Rule 2210 (the “Excluded Sections”). With the exception of the Excluded Sections noted above, this profile contains offering materials prepared solely by Monogram Orthopaedics without the assistance of SI Securities, and not subject to FINRA Rule 2210 (the “Issuer Profile”). The Issuer Profile may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based on information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they are meant for illustrative purposes and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.


Company Highlights

  • Founded by practicing Mount Sinai orthopedic surgeon Douglas Unis, and led by a team of experts in the field of surgical robotics and implant design including former Senior Director of Robotics Development Program Management at Stryker and former Director of Engineering for Orchid Design
  • Secured deal with established orthopedic company to distribute FDA approved implants as a source of early revenue; also secured licensing rights to integrate critical FDA approved components into Monogram products
  • Collaborative study with the UCLA Biomechanics Laboratory demonstrated a 7x improvement in initial stability against the current standard, and collaborative research with University of Nebraska Medical Center revealed 72% less micromotion than current standard
  • Validated implants can be manufactured using 3D printing; Monogram’s 3D printed hip passed testing to simulate FDA tests (10 million cycles at 1,200 lbs)
  • Seven patents filed under Exclusive License Agreement as well as a Freedom-to-Operate search ("FTO") for Monogram's knee design with a robotic surgical approach

Fundraise Highlights

  • Total Amount Raised: US $5,082,184
  • Total Investors: 2286
  • Total Round Size: US $20,000,000
  • Raise Description:  Series A
  • Minimum Investment:  US $1,000 per investor
  • Security Type:  Preferred Equity
  • Pre-Money valuation :  US $21,250,000

We are using machine learning (AI), robotics, and 3D printing to improve joint replacement surgeries. We believe the synthesis of these three technologies will define the future of orthopedics.


Monogram is developing a novel approach to joint reconstruction.

Problem:

There are 1,658,200 total hip and knee replacements annually in the US. Over 14.5% of hips and 9.5% of knees fail. One-in-five patients are not satisfied with their knee replacement. Cemented implants are not ideal for younger active patients but remain widely used for knees (over 90%). Leading causes of revision include infection, mechanical loosening, implant failure, dislocation/instability, and fracture. Many of these complications are preventable with technology. Primary ankles, shoulders, and spine are also markets where problems persist that technology can solve.

最终痴汉电车3Innovation advances in orthopedics remain slow and inefficient. Large companies dominate with almost indistinguishable implants. Robots are costly, slow, and redundant. Most implants, even those approved for robotic placement, are also insertable with manual instruments. The enormous inefficiency has built nearly insurmountable barriers to entry, where the top four implant companies account for 76% of the $18B primary hip and knee markets.

Solution:

We use algorithms to plan optimized surgeries pre-operatively. Using patient data, we fabricate implants designed to increase stability and reduce size. We can do this cost-efficiently (with 3D printing) and with high accuracy (with surgical robotics). We are starting with knee implants but expect to develop implants for all joints (hips, ankles, shoulders, and spine). In collaboration with the UCLA Biomechanics Laboratory and the University of Nebraska Medical Center, our patented hip implants were a factor of 7x more stable, and our novel knee showed 73% less micromotion in varus-valgus rotation. Monogram has demonstrated superior restoration of the native anatomy. We showed up to a 13mm improvement in hip center placement.

Pitch Deck

Product & Service

Product:

Monogram is commercializing next-generation orthopedic implants for active young patients. The Monogram implants rely on natural biologic fixation without cement for long term stability in a smaller size. We are optimizing implant contact with design and high precision robotics.

Monogram's principal advantage is in the patents that protect our implant innovations and our methods of delivery. We have filed numerous patents to protect the implant designs, the methods of generation, the methods of insertion, and various improvements to the surgical workflow.

最终痴汉电车3Our long-term monetizable products will include a surgical robot, cutting tools, and navigation consumables, software, and implants.

Implants:

最终痴汉电车3Monogram believes the future of orthopedics is implants designed for active young patients. That means minimally invasive press-fit implants that reconstruct native anatomy and rely on natural biologic fixation, rather than cement. A tight fit and initial stability are critical for the long-life viability of press-fit implants. We have designed the Monogram implants to be more stable and less invasive (i.e., less bone removal) while precisely reconstructing the pre-arthritic anatomy.

最终痴汉电车3Generic implants aren't good enough. Generic hip stems have limited options to restore anatomy. Most hips are only available in two widths despite the human anatomic variation. Generic implant shapes are geometric and inorganic, which limits direct bone contact. Generic knee tibias rely on a flawed design premise of flat-on-flat with a central keel, which isn't optimal for peripheral loading. Monogram will focus on hips & knees, followed by ankles, shoulders, and spine.

Robotics:

最终痴汉电车3Manual bone preparation is often less accurate and subject to surgeon skill. Crude manual instrumentation can lead to suboptimal function outcomes and complications such as periprosthetic fracture, dislocation, leg length discrepancy, malalignment, poor ligament balancing, subsidence, and early loosening.

Monogram is developing a navigated robot with enhancements that will improve the surgeon workflow and cut execution. The robot has seven degrees-of-freedom (the range of motion) with sophisticated controls to optimize performance. The software is capable of simultaneously tracking and avoiding multiple objects at once. For example, surgeons can use tracked objects, such as retractors, to create virtual boundaries around sensitive tissues. 

Development:

Monogram has entered into a binding term sheet with an undisclosed orthopedic technology company. Pursuant to the agreement, the partner will supply Monogram FDA approved Total Knee implants and license to Monogram certain intellectual property rights and pursuant to which, Monogram will be consigned a specified number of FDA approved implant components. Monogram shall have the option, at its sole discretion, to relabel and otherwise remarket under Monogram's name and branding. Monogram will combine components of these FDA approved implants with the 3D printed Monogram implants to release its first product. The product will be a Monogram branded implant system insertable manually or robotically.

This model replicates a highly effective model successfully implemented by startups like Mako and Bluebelt. Monogram believes it has already secured the funding needed to commercialize this product within the next 21 months (assuming no FDA clinical trial request). This deal also gives Monogram funding support from an established orthopedic company with consignment inventory to support our early revenue.

Monogram will continue the rapid development of its robotic surgical system in parallel.  

By 2021:

最终痴汉电车3Monogram expects to be submitting a hybrid implant solution for FDA approval. 

Team Story

Dr. Douglas Unis, an attending orthopedic surgeon for the Icahn School of Medicine and Chief of Quality Improvement at Mount Sinai West, founded Monogram in 2016 after being awarded a grant from the prestigious ELabNYC biotech startup incubator. Following his deep passion for patient well-being, Monogram was born. After years of consulting with several orthopedic companies on various technologies, including on robotic surgical applications, Dr. Unis grew frustrated by the slow pace of innovation and a lack of focus on improving implant design. Dr. Unis realized that technology could mitigate the persistently high rates of failure and complication in primary joint replacements. He realized that advances in manufacturing, image processing, and robotics formed the ingredients for an entirely new way of thinking about orthopedics.

With an unassailable belief that the answer lies in the thoughtful synthesis of machine learning (AI), robotics, and 3D printing, Monogram Orthopaedics began.    

Founders and Officers

Douglas Unis, Md

Founder and Chief Medical Officer

Dr. Unis is a board certified orthopedic surgeon specializing in adult reconstructive surgery and is the founder and Chief Medical Officer of Monogram Orthopedics. Dr. Unis founded Monogram Orthopedics in 2015. Dr. Unis has served as an Associate Professor at the Icahn School of Medicine since November 2015 and has been a practicing surgeon since 2004. Dr. Unis has consulted with many orthopedic companies including Zimmer Biomet and Think Surgical. Prior to founding Monogram Othopedics Dr. Unis was a consultant with Think Surgical, working to help with the development of their robotic total hip and knee arthroplasty system. Dr. Unis is recognized as a leader and innovator in the NYC area, having performed one of the regions’ first muscle sparing anterior total hip replacement in 2005. Dr. Unis earned his BA from Duke University and Doctor of Medicine from Case Western Reserve University and later completing his residency at Northwestern University and a fellowship from Rush University in Adult Reconstruction.   

Douglas Unis, Md

Founder and Chief Medical Officer

Dr. Unis is a board certified orthopedic surgeon specializing in adult reconstructive surgery and is the founder and Chief Medical Officer of Monogram Orthopedics. Dr. Unis founded Monogram Orthopedics in 2015. Dr. Unis has served as an Associate Professor at the Icahn School of Medicine since November 2015 and has been a practicing surgeon since 2004. Dr. Unis has consulted with many orthopedic companies including Zimmer Biomet and Think Surgical. Prior to founding Monogram Othopedics Dr. Unis was a consultant with Think Surgical, working to help with the development of their robotic total hip and knee arthroplasty system. Dr. Unis is recognized as a leader and innovator in the NYC area, having performed one of the regions’ first muscle sparing anterior total hip replacement in 2005. Dr. Unis earned his BA from Duke University and Doctor of Medicine from Case Western Reserve University and later completing his residency at Northwestern University and a fellowship from Rush University in Adult Reconstruction.   

Benjamin Sexson

Chief Executive Officer

Mr. Benjamin Sexson is the Chief Executive Officer of Monogram Orthopedics. Prior to joining Monogram, Mr. Sexson served as the Director of Business Development at Pro-Dex, an OEM manufacturer of Orthopedic Robotic End-Effectors. In his tenure at Pro-Dex, Mr. Sexson was responsible for the development, management, and launch of a proprietary product solution, helping to negate a distribution agreement with a major strategic partner. In addition, Mr. Sexson helped land and negotiate two additional development agreements and helped to expand the company’s addressable markets from CMF to Thoracic, Trauma, Spine, and Extremities. Mr. Sexson is a named inventor on multiple patent applications at Pro-Dex. Prior to joining Pro-Dex, Mr. Sexson started Brides & Hairpins, a successful B2B retail brand that currently supplies Nordstrom, Bloomingdales, and Urban Outfitters. Prior to that Mr. Sexson worked in various finance positions and is a CFA Charterholder.  Mr. Sexson graduated with honors from Caltech in Mechanical Engineering.

Benjamin Sexson

最终痴汉电车3Chief Executive Officer

Mr. Benjamin Sexson is the Chief Executive Officer of Monogram Orthopedics. Prior to joining Monogram, Mr. Sexson served as the Director of Business Development at Pro-Dex, an OEM manufacturer of Orthopedic Robotic End-Effectors. In his tenure at Pro-Dex, Mr. Sexson was responsible for the development, management, and launch of a proprietary product solution, helping to negate a distribution agreement with a major strategic partner. In addition, Mr. Sexson helped land and negotiate two additional development agreements and helped to expand the company’s addressable markets from CMF to Thoracic, Trauma, Spine, and Extremities. Mr. Sexson is a named inventor on multiple patent applications at Pro-Dex. Prior to joining Pro-Dex, Mr. Sexson started Brides & Hairpins, a successful B2B retail brand that currently supplies Nordstrom, Bloomingdales, and Urban Outfitters. Prior to that Mr. Sexson worked in various finance positions and is a CFA Charterholder.  Mr. Sexson graduated with honors from Caltech in Mechanical Engineering.

Sherif Aly

最终痴汉电车3VP of Engineering

Sherif was instrumental in the development of the Mako Orthopedic Robot and Implant systems. After Stryker acquired Mako, Sherif was the Senior Director of Robotics Development Program Management, reporting to the VP of Robotics R&D. Most recently, Sherif was the VP of Engineering and Regulatory Affairs at Xenex Disinfection Systems. He holds his Ph.D. in Mechanical Engineering from Rutgers University.

Sherif Aly

最终痴汉电车3VP of Engineering

最终痴汉电车3Sherif was instrumental in the development of the Mako Orthopedic Robot and Implant systems. After Stryker acquired Mako, Sherif was the Senior Director of Robotics Development Program Management, reporting to the VP of Robotics R&D. Most recently, Sherif was the VP of Engineering and Regulatory Affairs at Xenex Disinfection Systems. He holds his Ph.D. in Mechanical Engineering from Rutgers University.

Chris Scifert

Director of Product Development Implants & Instruments

Before joining Monogram, Chris was the Director of Engineering for Orchid Design, a division of Orchid Orthopedic Solutions, a market-leading outsourced medical services. Chris has held various engineering management roles at Medtronic and Smith & Nephew and obtained a Ph.D. in Biomedical Engineering from the University of Iowa.

Chris Scifert

最终痴汉电车3Director of Product Development Implants & Instruments

Before joining Monogram, Chris was the Director of Engineering for Orchid Design, a division of Orchid Orthopedic Solutions, a market-leading outsourced medical services. Chris has held various engineering management roles at Medtronic and Smith & Nephew and obtained a Ph.D. in Biomedical Engineering from the University of Iowa.

Notable Advisors & Investors

Pro-dex Inc
Mount Sinai Innovation Partners
Accelerate NY Seed Fund
Laura Gilmour

最终痴汉电车3Advisor, Mentor, Medical

Sophia Sangiorgio, PhD

Advisor, Mentor, Biomechanics

Matt DiCicco

Advisor, Mentor, Robotics

Q&A with the Founder

  • 最终痴汉电车3Why SeedInvest vs. traditional VC funding?

    最终痴汉电车3Monogram management believes it is commercializing a "when" not "if" technology. Time to market and our first-mover advantage are crucial. We believe patient optimized (especially for active young patients) 3D printed press-fit implants inserted into robotically prepared cavities is the inevitable future of orthopedics. As such, we believe that time to market, and it follows execution, and a best-in-class team is critical to our success. We believe that we can compete on speed and efficiency as a lean startup, but we need to have top talent to do so. The challenge for startups, however, is finding the money to pay top talent before funding is secured. The reality is that most top-caliber engineers and project managers have real everyday responsibilities and need stable paychecks.

    How does a startup without any funding, get funding without a team? And how does a startup assemble a best-in-class team if it doesn't have money for salaries? Even with equity, most employees need paychecks. SeedInvest recognizes this chicken-and-egg problem and the challenge startups face of needing to hire talent to raise capital but needing capital to recruit talent. To address this challenge, SeedInvest does not require its platform companies to syndicate the full rounds before the close. Once platform companies hit their escrow targets, they get full access to the capital and have regular closes after that.

    Monogram was able to hit its escrow target of $2.75M and has been able to recruit top talent and accelerate its initiatives. SeedInvest has put us ahead of our internal goals.

  • What is your go-to-market strategy?

    最终痴汉电车3Monogram has entered into a binding term sheet with an undisclosed orthopedic technology company. Pursuant to the agreement, the partner will supply Monogram FDA approved Total Knee implants and license to Monogram certain intellectual property rights and pursuant to which, Monogram will be consigned a specified number of FDA approved implant components. Monogram shall have the option, at its sole discretion, to relabel and otherwise remarket under Monogram's name and branding. Monogram will combine components of these FDA approved implants with the 3D printed Monogram implants to release its first product. The product will be a Monogram branded implant system insertable manually or robotically.

    最终痴汉电车3This model replicates a highly effective model successfully implemented by startups like Mako and Bluebelt. Monogram believes it has already secured the funding needed to commercialize this product within the next 21 months (assuming no FDA clinical trial request). This deal also gives Monogram funding support from an established orthopedic company with consignment inventory to support our early revenue. Monogram will continue the rapid development of its robotic surgical system in parallel.

    最终痴汉电车3The discrete commercialization phases will consist of the following:

    Phase I:最终痴汉电车3 100% partner implants & instruments

    最终痴汉电车3Distribution of our orthopedic partner's Total Knee solution with their manual instrumentation to identified surgeon KOLs. Our surgeons will familiarize themselves with the existing FDA approved implants and instrumentation. Monogram has actively recruited a sales and marketing executive who will begin building the sales and distribution channels when the market normalizes.

    Phase II: 50% partner implants | 50% Monogram

    Monogram will introduce a patented press-fit tibia with external fixation and no keel, an exclusive Monogram jig, and a custom burr guide for bone preparation. Monogram believes this will accelerate and de-risk FDA submission. The solution will introduce a highly differentiated and clinically significant press-fit implant designed for active young patients. Ideally, our surgeon KOLs would already be familiar with the partner implants and instruments and would be swapping out the tibial component for the Monogram tibial component. Surgeons would execute the tibial resection with the existing generic instrumentation. The internal target for approval and release is in 2021 (assuming no clinical trial request from the FDA).

    Phase III:最终痴汉电车3 Robotic Release

    最终痴汉电车3Monogram would introduce its surgical robot for full execution of all bone cuts. Monogram would begin obtaining clinical data to validate the clinical value proposition long term.

    Phase IV:最终痴汉电车3 Full-Customization & New Market Launches

    最终痴汉电车3Our goal is to accelerate our time to market and de-risk the commercialization while driving significant clinical differentiation and capital efficiency. We expect to achieve revenue with tactical high-volume hospitals and academic institutions through the strategic relationships of our founders and sales leadership (actively recruiting). We believe this strategy will help us raise strategic growth capital that will facilitate more rapid growth. This growth will be a mix of in house and independent sales representatives. Comparable company analysis with Mako Surgical helps validate a market premium for FDA approved, differentiated products generating revenue. At the time of their IPO, Mako made $1.9m of revenue and raised $51M in an IPO at a $180M valuation.

  • Why can't someone else do this, and who are your closest competitors?

    Four companies dominate the orthopedic market; Stryker (ticker: SYK), Zimmer Biomet (ticker: ZBH), J&J (DepuySynthes, ticker: JNJ), and Smith & Nephew (ticker: SNN). These four companies enjoy approximately 76% of the joint replacement total market opportunity. None of these companies is using a surgical robot to execute CT based surgical plans with a navigated robot capable of actively milling optimized cavities. It is important to note that soft tissue robots like the Intuitive Surgical (ticker: ISRG) DaVinci robot are not Monogram competitors. Robots that rely on a "master-slave" control paradigm for minimally invasive surgical procedures are not designed or optimized for orthopedic bone preparation.

    Uncemented implants optimized for active young patients are new (less than 10% of knees today are uncemented). None of our competitors are using an actively milling robot to excavate high-accuracy bone cavities for placement of optimized press-fit implants from a CT based preoperative plan. Our approach is extremely technically challenging and would require significant course corrections for most of our competitors. For example, many of our competitors do not utilize image-based planning approaches. These "imageless" systems, in our view, cannot achieve the accuracies needed for custom milling.

    We have filed numerous patents with a favorable Freedom-To-Operate ("FTO") search. We have recruited a best-in-class team that has successfully commercialized robotics and implants with many lessons learned. We believe that we have a significant first-mover advantage with a substantial IP moat around our business.

  • 最终痴汉电车3Please describe your target customer.

    We are designing implants for active younger patients that use natural biologic fixation with minimal size and robotic bone preparation for high accuracy placement. The average patient age today is 65 years old, but many implants that get used are designed for older patients. The trend is towards younger and younger patients, but the implants need to keep up with the demands of an active lifestyle.

    Approximately 90% of knee implants today rely on cemented fixation, which is not ideal for young patients. Monogram believes that natural biologic fixation from press-fit implants is. We are developing more stable and minimally invasive press-fit implants. For the average patient, the time between the onset of pain and surgery is significant, often several years or even a decade. Many patients that enjoy activities like hiking, golfing, tennis, etc., put off needed surgery because they don't want to risk an unfortunate outcome that could compromise their activities. We believe we can significantly mitigate the risk of poor results with technology designed to normalize patient outcomes.

  • Please detail the current stage of your development.

    Monogram has put together a team of leading experts to commercialize our novel technology. We currently have a high functioning prototype that successfully autogenerated five patient-specific implants from a simulated specimen, autogenerated the robotic cut paths, and high-precision milled the cavities for each specimen for micromotion testing (this was the testing conducted for the UCLA micromotion studies). The most sophisticated aspect of our robotic execution is the software that controls the robotic arm.

    最终痴汉电车3Concerning implant validation, the primary determinant of the long term viability of an implant is the initial stability. For both our patented hips and our patented knees, we conducted rigorous testing. For the hip, our implant prototype specimens were tested against five manually inserted conventional implants to determine relative performance. The data validated superior placement of the anatomical center of rotation, higher surface area contact, and significantly decreased micromotion. Our knees testing was conducted at the University of Nebraska Medical Center, similarly with highly favorable results.

    For the surgical workflow, our prototype consists of image processing and implant & cut path generation algorithms with a surgeon interface GUI. These algorithms interface with our robotic system, which includes a registration protocol, a real-time camera tracking system, a milling end-effector, and various other user enhancements. Our robot can mill the implant cavities from the cut-paths autogenerated by our algorithm. The result is a stable implant that restores the native anatomy in a minimally invasive form factor. A press-fit (natural fixation) minimally invasive and durable implant is optimal for active patients with a desire to continue their sporting activities.

  • The Q&A with the Founder is based on due diligence activities conducted by SI Securities, LLC. The verbal and/or written responses transcribed above may have been modified to address grammatical, typographical, or factual errors, or by special request of the company to protect confidential information.

    Term Sheet

    Fundraising Description

  • Round type:
    Series A

  • Round size:
    US $20,000,000

  • Raised to date:
    US $5,082,184

  • Minimum investment:
    US $1,000

  • Target Minimum:
    US $2,750,000
  • Key Terms

  • Security Type:
    Preferred Equity

  • Share price:
    US $4.0

  • Pre-Money valuation:
    US $21,250,000

  • Option pool:
    2.0%

  • Liquidation preference:
    1.0x
  • Additional Terms

  • Custody of Shares

    Investors who invest $50,000 or less will have their securities held in trust with a Custodian that will serve as a single shareholder of record. These investors will be subject to the Custodian’s Account Agreement, including the electronic delivery of all required information. 


  • Closing Conditions

    SI Securities, LLC has the authority to prevent a closing from occurring if it determines, in its sole discretion, that this investment is no longer suitable at the time of the closing, which includes, but is not limited to, the Company raising at least US $2,750,000 in connection to the current round.


  • Use of Proceeds

    Investor Perks

    $1,000 – Quarterly investor updates.

    $25,000 最终痴汉电车3– Above plus newly designed Monogram t-shirt.

    $100,000 – Above plus participation in regularly scheduled quarterly call with Monogram senior management.

    $250,000 – Above plus arranged, paid airfare (domestic or domestic equivalent airfare towards international) to a Monogram location for in-person investor tour and a one-time dinner with management. Also includes invitation to annual updates (dinners, calls, etc.) with the Monogram senior management team.

    最终痴汉电车3It is advised that you consult a tax professional to fully understand any potential tax implications of receiving investor perks before making an investment.

    Prior Rounds

    The graph below illustrates the valuation cap or the pre-money valuation of Monogram Orthopaedics's prior rounds by year.


    This chart does not represent guarantees of future valuation growth and/or declines.

    Pre-Seed

  • Round Size
    US $564,000
  • Closed Date
    Dec 14, 2017
  • Security Type
    Convertible Note
  • Valuation Cap
    US $6,000,000
  • Other

  • Round Size
    US $823,000
  • Closed Date
    Dec 21, 2018
  • Security Type
    Convertible Note
  • Valuation Cap
    US $6,000,000
  • Bridge

  • Round Size
    US $275,000
  • Closed Date
    Dec 20, 2018
  • Security Type
    Convertible Note
  • Valuation Cap
    US $8,000,000
  • Other

  • Round Size
    US $50,000
  • Closed Date
    Dec 24, 2018
  • Security Type
    Convertible Note
  • Valuation Cap
    US $10,000,000
  • Market Landscape

    Global reconstructive joint market (in millions)


    The Monogram implants are uncemented and inserted with robotics. We have not identified any robotically inserted press-fit patient-specific implants on the market – for example, the ConforMIS implants are cemented implants inserted with manual instruments.  The Monogram implants are designed to optimize the bone-to-implant interface for optimized natural fixation.

    The level of competition in the orthopedic market is high, with several large, well-capitalized competitors holding a majority share of the market. Currently, we are not aware of any well-known orthopedic companies that broadly offer robotic technology in combination with surgical navigation for the insertion of patient-specific orthopedic implants. The top five market participants in the joint replacement devices market are Zimmer Biomet, DePuySynthes, Stryker, and Smith & Nephew. These companies dominate the market for orthopedic products with around 76% market share. These companies, as well as other companies like ConforMIS,  offer implant solutions, including (depending on the competitor) a combination of conventional instruments and generic implants, robotics and generic implants, or patient-specific instruments and patient-specific implants.

    The market exhibits oligopolistic behaviors as it relates to pricing and differentiation. The average sale price (ASP) of total hip implant components was $5,136 in 2017 and $4,547 for total knee. The range of pricing for these components is not widely distributed. The bill of materials for implants are generally quite similar between vendors and many of the large implant companies outsource a meaningful percentage of their manufacturing to large ISO 13584 contract manufacturers.

    We believe that utilization  and market share over the long term are driven by surgeon adoption which is driven by the clinical benefits of the technology.

    Risks and Disclosures

    We have a limited operating history upon which you can evaluate our performance, and have not yet generated profits. Accordingly, our prospects must be considered in light of the risks that any new company encounters. Our company was incorporated under the laws of the State of Delaware on April 21,2016, and we have not yet generated profits. The likelihood of our creation of a viable business must be considered in light of the problems, expenses, difficulties, complications, and delays frequently encountered in connection with the growth of a business, operation in a competitive industry, and the continued development of our technology and products. We anticipate that our operating expenses will increase for the near future, and there is no assurance that we will be profitable in the near future. You should consider our business, operations and prospects in light of the risks, expenses and challenges faced as an emerging growth company.

    The auditor included a “going concern” note in its audit report. We may not have enough funds to sustain the business until it becomes profitable. Even if we raise funds through this offering, we may not accurately anticipate how quickly we may use the funds and whether these funds are sufficient to bring the business to profitability.

    Our technology is not yet fully-developed, and there is no guarantee that we will successfully develop our technology. Monogram is developing complex technology that will require significant technical and regulatory expertise to develop and commercialize. If we are unable to successfully develop and commercialize our technology and products, it will significantly affect our viability as a company.

    We are subject to substantial governmental regulation relating to the manufacturing, labeling and marketing of our products, and will continue to be for the lifetime of our company. The FDA and other governmental authorities in the United States regulate the manufacturing, labeling and marketing of our products. The process of obtaining regulatory approvals to market a medical device can be expensive and lengthy and applications may take a long time to be approved, if they are approved at all. Our compliance with the quality system, medical device reporting regulations and other laws and regulations applicable to the manufacturing of products within our facilities and those contracted by third parties is subject to periodic inspections by the FDA and other governmental authorities. Complying with regulations, and, if necessary, remediary actions can be significantly expensive. Failure to comply with applicable regulatory requirements may subject us to a range of sanctions, including substantial fines, warning letters that require corrective action, product seizures, recalls, halting product manufacturing, revocation of approvals, exclusion from future participation in government healthcare programs, substantial fines and criminal prosecution.

    We are subject to federal and state healthcare regulations and laws relating to anti-bribery and anti-corruption, and non-compliance with such laws could lead to significant penalties. State and Federal anti-bribery laws, healthcare fraud and abuse laws dictate how we conduct the relationships that we and our distributors and others that market our products have with healthcare professionals, such as physicians and hospitals. We also must comply with a variety of other laws that protect the privacy of individually identifiable healthcare information. These laws and regulations are broad in scope and are subject to evolving interpretation and we could be required to incur substantial costs to monitor compliance or to alter our practices if we are found not to be in compliance. In addition, violations of these laws may be punishable by criminal or civil sanctions, including substantial fines, imprisonment of current or former employees and exclusion from participation in governmental healthcare programs.

    Government regulations and other legal requirements affecting our company are subject to change. Such change could have a material adverse effect on our business. We operate in a complex, highly regulated environment. The numerous federal, state and local regulations that our business is subject to include, but are not limited to: federal and state registration and regulation of medical devices; applicable governmental payor regulations including Medicare and Medicaid; data privacy and security laws and regulations including those under the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”); the Affordable Care Act (“ACA”) or any successor to that act; laws and regulations relating to the protection of the environment and health and safety matters, including those governing exposure to, and the management and disposal of, hazardous substances; regulations regarding food and drug safety including those of the Food and Drug Administration (“FDA”), and consumer protection and safety regulations including those of the Consumer Product Safety Commission, as well as state regulatory authorities, governing the availability, sale, advertisement and promotion of products we sell; federal and state laws governing health care fraud and abuse; anti-kickback laws; false claims laws; and laws against the corporate practice of medicine. The FDA and state regulatory authorities have broad enforcement powers, including the ability to seize or recall products and impose significant criminal, civil and administrative sanctions for violations of these laws and regulations.

    Changes in laws, regulations and policies and the related interpretations and enforcement practices may significantly affect our cost of doing business as we endeavor maintain compliance with such new policies and laws. Changes in laws, regulations and policies and the related interpretations and enforcement practices generally cannot be predicted may require extensive system and operational changes. Noncompliance with applicable laws and regulations could result in civil and criminal penalties that could adversely affect our business, including: suspension of payments from government programs; loss of required government certifications; loss of authorizations to participate in or exclusion from government programs, including the Medicare and Medicaid programs; loss of licenses; and significant fines or monetary penalties. Any failure to comply with applicable regulatory requirements could result in significant legal and financial exposure, damage our reputation, and have a material adverse effect on our business operations, financial condition and results of operations. 

    We have not yet obtained clearance of our products by the U. S. Food and Drug Administration, or FDA, which is critical to our business plan. In order to sell our products, we must obtain market clearance from the Food and Drug Administration (“FDA”) under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, or the FDCA (see “The Company’s Business – Regulation.”).If Monogram is unable to obtain Section 510(k) clearance, we will not be able to sell our products, and it is unlikely that we will be able to continue to operate as a going concern. In addition, the FDA may request clinical data with our 510 (k) submission. The FDA has indicated an increased focus on robotic technologies that perform automated operations and may request clinical data for our robot and/or implants. If the FDA requests such information, it will materially and adversely impact our development timeline and increase the cost to obtain market clearance. These factors combined may impact our ability to continue to operate as a going concern.

    We anticipate initially sustaining operating losses. It is anticipated that we will initially sustain operating losses in seeking Section 510(k) clearance. Our ability to become profitable depends on obtaining 510(k) clearance, and subsequent success in licensing and selling of products. There can be no assurance that this will occur. Unanticipated problems and expenses are often encountered in offering new products which may impact whether the company is successful. Furthermore, we may encounter substantial delays and unexpected expenses related to development, technological changes, marketing, regulatory requirements and changes to such requirements or other unforeseen difficulties. There can be no assurance that we will ever become profitable. If the company sustains losses over an extended period of time, it may be unable to continue in business.

    Our products may not gain market acceptance among hospitals, surgeons, physicians, patients, healthcare payors and the medical community. A critical element in our commercialization strategy is to persuade the medical community on the efficacy of our products and to educate then on their safe and effective use. Surgeons, physicians and hospitals may not perceive the benefits of our products and may be unwilling to change from the devices they are currently using. A number of factors may limit the market acceptance of our products, including the following:

    • rate of adoption by healthcare practitioners;
    • rate of a product’s acceptance by the target population;
    • timing of market entry relative to competitive products;
    • availability of third-party reimbursement;
    • government review and approval requirements;
    • extent of marketing efforts by us and third-party distributors or agents retained by us; and
    • side effects or unfavorable publicity concerning our products or similar products.

    最终痴汉电车3Our inability to successfully commercialize our products will have a material adverse effect on the value of your investment.

    We could be adversely affected by product liability, personal injury or other health and safety issues. We could be adversely impacted by the supply of defective products. We are also exposed to risks relating to the surgical robotic technology services and products we provide. Defective products or errors in our technology could lead to serious injury or death. Product liability or personal injury claims may be asserted against us with respect to any of the products we supply or services we provide. Monogram is also liable for harms caused by any faults in raw materials or products supplied by third-party manufacturers and suppliers that our company utilizes. It is our responsibility to have a quality management system in place and to audit our suppliers to ensure that products supplied to our company meet proper standards. Should a product or other liability issues arise, the coverage limits under insurance programs and the indemnification amounts available to us may not be adequate to protect us against claims and judgments. We also may not be able to maintain such insurance on acceptable terms in the future. We could suffer significant reputational damage and financial liability if we experience any of the foregoing health and safety issues or incidents, which could have a material adverse effect on our business operations, financial condition and results of operations.

    If third-party payors fail to provide appropriate levels of reimbursement for the use of our products, our revenues could be adversely affected. Sales of our products depend on the availability of adequate reimbursement from third-party payors. In each market in which we do business, our inability to obtain reimbursement approval or the failure of third-party payors to reimburse health care providers at a level which justifies the use of our products instead of cheaper alternatives will hurt our business.

    Moreover, we are unable to predict what changes will be made to the reimbursement methodologies used by third-party payors in the future. Changes in political, economic and regulatory influences may significantly affect healthcare financing and reimbursement practices. For example, there have been multiple attempts through legislative action and legal challenges to repeal or amend the ACA. We cannot predict whether current or future efforts to repeal or amend these laws will be successful, nor can we predict the impact that such a repeal or amendment and any subsequent legislation would have on our business and reimbursement levels. There have also been a number of other proposals and enactments by the federal government and various states to reduce Medicaid reimbursement levels in response to budget deficits, and we expect additional proposals in the future. We cannot assure you that recent or future changes reimbursement policies and practices will not materially and adversely affect our results of operations. Efforts to control healthcare costs, including costs of reconstructive joint replacement, are continuous and reductions in third party reimbursement levels could materially and adversely affect our results of operations.

    We rely on a licensing agreement with Icahn School of Medicine at Mount Sinai. We are party to a licensing agreement (and related option agreement) with Icahn School of Medicine at Mount Sinai (“Mount Sinai”) pursuant to which Mount Sinai has granted Monogram an exclusive license to patents related to customizable bone implants, surgical planning software, and surgical robots (see “The Company’s Business – Intellectual Property”). The patent, software, technical information, know how, etc licensed under this agreement is integral to our company’s core products and technology. As such, we are reliant on the licensing agreement with Mount Sinai to operate our business. Under the terms of our licensing agreement, Mount Sinai has the right to terminate our license for the patent if we materially breach any of our obligations under the licensing agreement. Further, the licensing agreement expires upon the later of (i) 12 years from the first commercial sale of such any product that we sell using the intellectual property covered in the licensed patent or (ii) expiration of the licensed patent. If our arrangement with Mount Sinai were to end, we would no longer be able to use the intellectual property covered by the patent, which could significantly affect our business.

    We operate in a highly competitive industry that is dominated by several very large, well-capitalized market leaders and is constantly evolving. New entrants to the market, existing competitor actions, or other changes in market dynamics could adversely impact us. The level of competition in the orthopaedic market is high, with several very large, well-capitalized competitors holding a majority share of the market. Changes in market dynamics or actions of competitors or manufacturers, including industry consolidation and the emergence of new competitors and strategic alliances, could materially and adversely impact our business. Disruptive innovation by existing or new competitors could alter the competitive landscape in the future and require us to accurately identify and assess such changes and make timely and effective changes to our strategies and business model to compete effectively.

    Currently, we are not aware of any well-known orthopaedic companies that broadly offer robotic technology in combination with surgical navigation for the insertion of patient specific orthopaedic implants. Nonetheless, many of our competitors in this market have significant financial resources and may seek to extend their robotics and orthopaedic implant technology to accommodate the robotic insertion of patient specific implants. Further, a number of companies offer surgical navigation systems for use in arthroplasty procedures that provide a minimally invasive means of viewing the anatomical site. As such, other companies may create similar technology and/or products that we are producing, which would increase competition in our industry. As competition increases, a significant increase in general pricing pressures could occur, which could require us to reevaluate our pricing structures to remain competitive. For example, if we are not able to anticipate and successfully respond to changes in market conditions, it could result in a loss of customers or renewal of contracts or arrangements on less favorable terms.

    Our company does not currently hold any patents on its products or technology. Monogram Orthopaedics currently licenses 5 provisional patents, which includes a patent application with the USPTO, 2 provisional patent applications with the USPTO, and is in the process of submitting 2 additional patent applications to the USPTO (see “The Company’s Business – Intellectual Property”). As of the date of this Offering, the company has not been issued any patents. There is no guarantee that the company will ever be issued patents on the applications it has submitted or has licensed. Our success depends to a significant degree upon the protection of our products and technology. If we are unable to secure patents for our products and technology, other companies with greater resources may copy our technology and/or products, or improve upon them, putting us at a disadvantage to our competitors.

    Successful infringement claims against us could result in significant monetary liability or prevent us from selling some of our products. If successfully developed, our products and technology may be highly disruptive to a very large and growing market. Our competitors are well capitalized with significant intellectual property protection and resources, and may initiate infringement lawsuits against our company. Such litigation could be expensive and could also prevent us from selling our products, which would significantly harm our ability to grow our business as planned.

    Our failure to attract and retain highly qualified personnel in the future could harm our business. As the company grows, it will be required to hire and attract additional qualified professionals such as software engineers, robotics engineers, machine vision and machine learning experts, biomechanical engineers, project managers, regulatory professionals, sales and marketing professionals, accounting, legal, and finance experts. The company may not be able to locate or attract qualified individuals for such positions, which will affect the company’s ability to grow and expand its business.

    We rely on third party manufacturers and service providers. Our third party partners provide a variety of essential business functions, including distribution, manufacturing, and many others. It is possible that some of these third parties will fail to perform their services or will perform them in an unacceptable manner. If we encounter problems with one or more of these parties and they fail to perform to expectations, it could have a material adverse impact on the company.

    Our future success is dependent on the continued service of our small management team. Monogram is managed by three directors and one executive officer. Our success is dependent on their ability to manage all aspects of our business effectively. Because we are relying on our small management team, we lack certain business development resources that may hurt our ability to grow our business. Any loss of key members of our executive team could have a negative impact on our ability to manage and grow our business effectively. We do not maintain a key person life insurance policy on any of the members of our senior management team. As a result, we would have no way to cover the financial loss if we were to lose the services of our directors or officers.

    We expect to raise additional capital through equity and/or debt offerings to support our working capital requirements and operating losses. In order to fund future growth and development, the company will likely need to raise additional funds in the future by offering shares of its Common or Preferred Stock and/or other classes of equity, or debt that convert into shares of common or Preferred Stock, any of which offerings would dilute the ownership percentage of investors in this offering. See “Dilution.” Furthermore, if the company raises capital through debt, the holders of our debt would have priority over holders of common and Preferred Stock and the company may be required to accept terms that restrict its ability to incur more debt. We cannot assure you that the necessary funds will be available on a timely basis, on favorable terms, or at all, or that such funds if raised, would be sufficient. The level and timing of future expenditure will depend on a number of factors, many of which are outside our control. If we are not able to obtain additional capital on acceptable terms, or at all, we may be forced to curtail or abandon our growth plans, which could adversely impact the company, its business, development, financial condition, operating results or prospects.

    Any valuation at this stage is difficult to assess. The valuation for this Offering was established by the company. Unlike listed companies that are valued publicly through market-driven stock prices, the valuation of private companies, especially early-stage companies, is difficult to assess and you may risk overpaying for your investment.

    If we cannot raise sufficient funds, we will not succeed. We are offering shares of our Series A Preferred Stock in the amount of up to $20,000,000 in this Offering on a best-efforts basis and may not raise the complete amount. Even if the maximum amount is raised, we are likely to need additional funds in the future in order to grow, and if we cannot raise those funds for whatever reason, including reasons relating to the company itself or to the broader economy, the company may not survive. If we raise a substantially lesser amount than the Maximum Raise, we will have to find other sources of funding for some of the plans outlined in “Use of Proceeds To Issuer.”.

    All of our assets are pledged as collateral to a lender. We have entered into convertible promissory notes with lenders that contain covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other things:

    • petition for bankruptcy;
    • assignment of the notes to other creditors;
    • appointment of a receiver of any property of the company; and
    • consolidate, merge, sell or otherwise dispose of all or substantially all of our assets.

    A breach of any of these covenants could result in a default under the notes Upon the occurrence of an event of default under these notes, the lender could elect to declare all amounts outstanding thereunder to be immediately due and payable. We have pledged all of our assets as collateral under our credit facility

    General Risks and Disclosures

    Start-up investing is risky. Investing in startups is very risky, highly speculative, and should not be made by anyone who cannot afford to lose their entire investment. Unlike an investment in a mature business where there is a track record of revenue and income, the success of a startup or early-stage venture often relies on the development of a new product or service that may or may not find a market. Before investing, you should carefully consider the specific risks and disclosures related to both this offering type and the company which can be found in this company profile and the documents in the data room below.

    Your shares are not easily transferable.最终痴汉电车3 You should not plan on being able to readily transfer and/or resell your security. Currently there is no market or liquidity for these shares and the company does not have any plans to list these shares on an exchange or other secondary market. At some point the company may choose to do so, but until then you should plan to hold your investment for a significant period of time before a "liquidation event" occurs. A "liquidation event" is when the company either lists their shares on an exchange, is acquired, or goes bankrupt.

    The Company may not pay dividends for the foreseeable future. Unless otherwise specified in the offering documents and subject to state law, you are not entitled to receive any dividends on your interest in the Company. Accordingly, any potential investor who anticipates the need for current dividends or income from an investment should not purchase any of the securities offered on the Site.

    Valuation and capitalization. Unlike listed companies that are valued publicly through market-driven stock prices, the valuation of private companies, especially startups, is difficult to assess and you may risk overpaying for your investment. In addition, there may be additional classes of equity with rights that are superior to the class of equity being sold.

    You may only receive limited disclosure. While the company must disclose certain information, since the company is at an early-stage they may only be able to provide limited information about its business plan and operations because it does not have fully developed operations or a long history. The company may also only obligated to file information periodically regarding its business, including financial statements. A publicly listed company, in contrast, is required to file annual and quarterly reports and promptly disclose certain events — through continuing disclosure that you can use to evaluate the status of your investment.

    Investment in personnel. An early-stage investment is also an investment in the entrepreneur or management of the company. Being able to execute on the business plan is often an important factor in whether the business is viable and successful. You should be aware that a portion of your investment may fund the compensation of the company's employees, including its management. You should carefully review any disclosure regarding the company's use of proceeds.

    Possibility of fraud.最终痴汉电车3 In light of the relative ease with which early-stage companies can raise funds, it may be the case that certain opportunities turn out to be money-losing fraudulent schemes. As with other investments, there is no guarantee that investments will be immune from fraud.

    Lack of professional guidance. Many successful companies partially attribute their early success to the guidance of professional early-stage investors (e.g., angel investors and venture capital firms). These investors often negotiate for seats on the company's board of directors and play an important role through their resources, contacts and experience in assisting early-stage companies in executing on their business plans. An early-stage company may not have the benefit of such professional investors.

    Representatives of SI Securities, LLC are affiliated with SI Advisors, LLC ("SI Advisors")最终痴汉电车3 Representatives of SI Securities, LLC are affiliated with SI Advisors, LLC ("SI Advisors"). SI Advisors is an exempt investment advisor that acts as the General Partner of SI Selections Fund I, L.P. ("SI Selections Fund"). SI Selections Fund is an early stage venture capital fund owned by third-party investors. From time to time, SI Selections Fund may invest in offerings made available on the SeedInvest platform, including this offering. Investments made by SI Selections Fund may be counted towards the total funds raised necessary to reach the minimum funding target as disclosed in the applicable offering materials.

    Monogram Orthopaedics's Offering Circular

    最终痴汉电车3The offering circular is the legal document filed with the SEC for a Regulation A offering and provides facts that an investor needs to make an informed investment decision. The offering circular includes an overview of company and company's business, historical financials and capitalization, and key risk factors.

    Download Monogram Orthopaedics's  Offering Circular here.

    Frequently Asked Questions

    About Reg A Offerings
    What does it mean that the SEC has qualified this offering?

    "The SEC has qualified this offering" means the SEC has permitted Monogram Orthopaedics to offer for sale the securities described in the Offering Circular to investors such as you. The SEC is not judging the merits, accuracy, or completeness of the offering and information in the Offering Circular.


    Making an Investment in Monogram Orthopaedics
    How does investing work?

    When you complete your investment on SeedInvest, your money will be transferred to an escrow account where an independent escrow agent will watch over your investment until it is accepted by Monogram Orthopaedics. Once Monogram Orthopaedics accepts your investment, and certain regulatory procedures are completed, your money will be transferred from the escrow account to Monogram Orthopaedics in exchange for your securities. At that point, you will be a proud owner in Monogram Orthopaedics.


    What is the difference between preferred equity and a convertible note?

    Preferred equity最终痴汉电车3 is usually issued to outside investors and carries rights and conditions that are different from that of common stock. For example, preferred equity may include rights that prevent or minimize the effects of dilution or grants special privileges in situations when the company is sold.

    A convertible note最终痴汉电车3 is a unique form of debt that converts into equity, usually in conjunction with a future financing round. The investor effectively loans money to a startup with the expectation that they will receive equity in the company in the future at a discounted price per share when the company raises its next round of financing.

    To learn more about startup investment types check out “How to Choose a Startup Investment”最终痴汉电车3 in our academy.


    What will I need to complete my investment?

    To make an investment, you will need the following information readily available:

    1. Personal information such as your current address and phone number
    2. Employment and employer information
    3. Net worth and income information
    4. Social Security Number or passport
    5. ABA bank routing number and checking account number (typically found on a personal check or bank statement)

    What if I change my mind about investing?

    Until a closing occurs, you may cancel your investment at any time, for any reason. You will receive an email when the closing occurs and your securities have been issued. If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To cancel your investment, please go to your portfolio page by clicking your profile icon in the top right corner.


    After My Investment
    How can I sell my securities in the future?

    Currently there is no market or liquidity for these securities. Right now Monogram Orthopaedics does not plan to list these securities on a national exchange or another secondary market. At some point Monogram Orthopaedics may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when Monogram Orthopaedics either lists their securities on an exchange, is acquired, or goes bankrupt.


    How do I keep track of this investment?

    最终痴汉电车3You can return to SeedInvest at any time to view your portfolio of investments and obtain a summary statement.


    Other General Questions
    What is this page about?

    This is Monogram Orthopaedics's fundraising profile page, where you can find information that may be helpful for you to make an investment decision in their company. The information on this page includes the company overview, team bios, and the risks and disclosures related to this investment opportunity. You will also find a copy of the Monogram Orthopaedics's Offering Circular, which has been qualified by the SEC. The Offering Circular includes important details about Monogram Orthopaedics's fundraise that you should review before investing.


    What are the risks of this investment?

    最终痴汉电车3This investment is highly speculative and should not be made by anyone who cannot afford to risk the entire investment amount. In addition to these risks, you should carefully consider the specific information and risks disclosed in Monogram Orthopaedics’s profile and Offering Circular.


    秒速赛车【gd1133.com光大彩票】-新闻 秒速赛车【gd1100.com光大彩票】-法治 秒速赛车【gd1144.com光大彩票】-案件 秒速赛车【gd1155.com光大彩票】-检察 秒速赛车【gd1166.com光大彩票】-理论 秒速赛车【gd1177.com光大彩票】-新媒体 秒速赛车【gd9900.com光大彩票】-视频 秒速赛车【gd9911.com光大彩票】-评论 秒速赛车【gd9922.com光大彩票】-文化 秒速赛车【gd9933.com光大彩票】-人物 秒速赛车【gd9944.com光大彩票】-舆情 秒速赛车【gd9955.com光大彩票】-装备 最终痴汉电车3 秒速赛车【gd9977.com光大彩票】-今日推荐 秒速赛车【gd1133.com光大彩票】-图片聚焦 秒速赛车【gd1100.com光大彩票】-以案说法 秒速赛车【gd1144.com光大彩票】-检察视界 秒速赛车【gd1155.com光大彩票】-城东区 秒速赛车【gd1166.com光大彩票】-城中区 秒速赛车【gd1177.com光大彩票】-城西区 秒速赛车【gd9900.com光大彩票】-城北区 秒速赛车【gd9911.com光大彩票】-大通县 秒速赛车【gd9922.com光大彩票】-湟中县 秒速赛车【gd9933.com光大彩票】-湟源县 秒速赛车【gd9944.com光大彩票】-经济技术开发区 秒速赛车【gd9955.com光大彩票】-城南新区 秒速赛车【gd9977.com光大彩票】-高新技术开发区 秒速赛车【gd1133.com光大彩票】-海湖新区 秒速赛车【gd1100.com光大彩票】-最终痴汉电车3 秒速赛车【gd1144.com光大彩票】-滚动 秒速赛车【gd1155.com光大彩票】-国内 秒速赛车【gd1166.com光大彩票】-国际 秒速赛车【gd1177.com光大彩票】-军事 秒速赛车【gd9900.com光大彩票】-社会 秒速赛车【gd9911.com光大彩票】-财经 秒速赛车【gd9922.com光大彩票】-产经 秒速赛车【gd9933.com光大彩票】-房产 秒速赛车【gd9944.com光大彩票】-金融 秒速赛车【gd9955.com光大彩票】-证券 秒速赛车【gd9977.com光大彩票】-汽车 秒速赛车【gd1133.com光大彩票】-IT 秒速赛车【gd1100.com光大彩票】-能源 秒速赛车【gd1144.com光大彩票】-港澳 秒速赛车【gd1155.com光大彩票】-台湾 秒速赛车【gd1166.com光大彩票】-华人 秒速赛车【gd1177.com光大彩票】-侨网 秒速赛车【gd9900.com光大彩票】-经纬 秒速赛车【gd9911.com光大彩票】-English 秒速赛车【gd9922.com光大彩票】-图片 秒速赛车【gd9933.com光大彩票】-视频 秒速赛车【gd9944.com光大彩票】-直播 北京PK10【gd9955.com光大彩票】-娱乐 PK10开奖【gd9977.com光大彩票】-体育 pk10平台【gd1133.com光大彩票】-文化 Pk10计划【gd1100.com光大彩票】-健康 pk10网址【gd1144.com光大彩票】-生活 pk10开户【gd1155.com光大彩票】-葡萄酒 pk10赛车【gd1166.com光大彩票】-微视界 PK10投注平台【gd1177.com光大彩票】-演出 PK10注册【gd9900.com光大彩票】-专题 PK10开户【gd9911.com光大彩票】-理论 北京PK10【gd9922.com光大彩票】-新媒体 PK10开奖【gd9933.com光大彩票】-供稿 pk10平台【gd9944.com光大彩票】-新闻 Pk10计划【gd9955.com光大彩票】-时事 pk10网址【gd9977.com光大彩票】-视频 pk10开户【gd1133.com光大彩票】-评论 pk10赛车【gd1100.com光大彩票】-股票 PK10投注平台【gd1144.com光大彩票】-区块链 PK10注册【gd1155.com光大彩票】-港股 PK10开户【gd1166.com光大彩票】-科创 北京PK10【gd1177.com光大彩票】-基金 PK10开奖【gd9900.com光大彩票】-私募 pk10平台【gd9911.com光大彩票】-理财 Pk10计划【gd9922.com光大彩票】-信托 pk10网址【gd9933.com光大彩票】-P2P pk10开户【gd9944.com光大彩票】-科技 pk10赛车【gd9955.com光大彩票】-债券 PK10投注平台【gd9977.com光大彩票】-互金 PK10注册【gd1133.com光大彩票】-期货 PK10开户【gd1100.com光大彩票】-原油 北京PK10【gd1144.com光大彩票】-大宗 PK10开奖【gd1155.com光大彩票】-期指 pk10平台【gd1166.com光大彩票】-保险 Pk10计划【gd1177.com光大彩票】-银行 pk10网址【gd9900.com光大彩票】-黄金 pk10开户【gd9911.com光大彩票】-外汇 pk10赛车【gd9922.com光大彩票】-行情 PK10投注平台【gd9933.com光大彩票】-数据 PK10注册【gd9944.com光大彩票】-房产 PK10开户【gd9955.com光大彩票】-汽车 北京PK10【gd9977.com光大彩票】-博客 PK10开奖【gd1133.com光大彩票】-农金 pk10平台【gd1100.com光大彩票】-名家 Pk10计划【gd1144.com光大彩票】-消金 pk10网址【gd1155.com光大彩票】-美股 pk10开户【gd1166.com光大彩票】-创投 pk10赛车【gd1177.com光大彩票】-游戏 PK10投注平台【gd9900.com光大彩票】-滚动 PK10注册【gd9911.com光大彩票】-新浪 PK10开户【gd9922.com光大彩票】-正义网